The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Hutchmed Share News (HCM)

Hutchmed Information

Buy HCM Shares
Add HCM to Watchlist
Add HCM to Alert

Share Price Information for Hutchmed (HCM)

London Stock Exchange

Share Price is delayed by 15 minutes

Share Price: 310.00

Bid: 307.00

Ask: 312.00

Change: 0.00 (0.00%)

Spread: 5.00 (1.629%)

Open: 311.00

High: 314.00

Low: 303.00

Prev. Close: 310.00

HCM Live Price

Last checked at -

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

Mon, 10th Aug 2020 11:04

Hutchison China MediTech Ltd - Hong Kong-based biopharmaceutical company - Receives scientific advice from European Medicines Agency's Committee for Medicinal Products for Human Use, for surufatnib for the treatment of patients with advanced neuroendocrine tumours. Based on advice, group concludes that completed studies on tumours both pancreatic and non-pancreatic, along with existing data, could form the basis for supporting a marketing authorisation application. Submission is planned for 2021, following submission to the US Food & Drug Administration.

Current stock price: 455.00 pence

Year-to-date change: up 20%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

1 Nov 2021 09:14

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

28 Oct 2021 21:59

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

29 Sep 2021 11:08

Hutchmed China sells joint venture stake for USD169 million

Hutchmed China sells joint venture stake for USD169 million

21 Sep 2021 10:51

Hutchmed starts drug combination trial for neuroendocrine tumours

Hutchmed starts drug combination trial for neuroendocrine tumours

20 Sep 2021 09:09

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

13 Sep 2021 10:22

Hutchmed China's amdizalisib secures breakthrough therapy designation

Hutchmed China's amdizalisib secures breakthrough therapy designation

8 Sep 2021 13:49

Hutchmed, Astra launch drug combination trial to treat lung cancer

Hutchmed, Astra launch drug combination trial to treat lung cancer

6 Sep 2021 09:37

Hutchmed China to trade in Shanghai and Shenzhen through link scheme

Hutchmed China to trade in Shanghai and Shenzhen through link scheme

26 Aug 2021 10:38

Hutchmed launches trial into drug combination to treat breast cancer

Hutchmed launches trial into drug combination to treat breast cancer

9 Aug 2021 12:35

Hutchmed strikes collaboration deal with Epizyme

(Sharecast News) - Commercial-stage biotechnology company Hutchmed China announced a collaboration to research, develop, manufacture and commercialise 'Tazverik' in Greater China on Monday, including mainland China, Hong Kong, Macau and Taiwan.

9 Aug 2021 10:06

Hutchmed to partner with Epizyme on tumour-targetting treatment

Hutchmed to partner with Epizyme on tumour-targetting treatment

28 Jul 2021 14:51

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

28 Jul 2021 11:33

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

28 Jul 2021 10:58

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

21 Jul 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days